Tue, 17 Oct 2017 12:00:00 EDT EVALUATION OF A NEW FUNCTIONAL INSULIN THERAPY Condition: Type1diabetes Interventions: Other: New functional insulin therapy; Other: functional insulin therapy Sponsors: Central Hospital, Nancy, France; Central Hospital, Reims, France; Central Hospital, Toulouse, France; Central Hospital, Strasbourg, France; Central Hospital, Besançon, France; Central Hospital, Dijon, France; Central Hospital, Metz Thionville, France Not yet recruiting
Tue, 17 Oct 2017 12:00:00 EDT Locally Delivered 1% Metformin Gel in Peri-implantitis Condition: Peri-Implantitis Interventions: Drug: 1% local metformin gel; Procedure: Placebo Sponsor: King Saud University Completed
Tue, 17 Oct 2017 12:00:00 EDT STEMI and Incretins Conditions: STEMI; Coronary Artery Disease; Coronary Syndrome; Coronary Arteriosclerosis; Diabetes Interventions: Device: PCI and DES stenting; Drug: Incretins Sponsor: University of Campania "Luigi Vanvitelli" Completed
Mon, 16 Oct 2017 12:00:00 EDT Variation of Genes Controlling Carbohydrate and Lipid Metabolism Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Obesity; Insulin Resistance; Lipid Metabolism Disorders; PreDiabetes Intervention: Sponsors: Turku University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Turku Recruiting
Fri, 13 Oct 2017 12:00:00 EDT Disease Prevention in Clinical Practice Base on Patient Specific Physiology Conditions: PreDiabetes; Insulin Resistance; Type2 Diabetes; NASH - Nonalcoholic Steatohepatitis; Diastolic Dysfunction; Dementia; Atrial Fibrillation; Cancer; Atherosclerosis; Carotid Plaque Intervention: Other: Lifestyle modification in routine care of patients Sponsor: Pacific Coast Family Medical Group Enrolling by invitation
Fri, 13 Oct 2017 12:00:00 EDT Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers Conditions: Liver Diseases, Alcoholic; Fibrosis Interventions: Diagnostic Test: transient elastography; Diagnostic Test: Enhanced liver fibrosis test; Diagnostic Test: Indirect serum markers of liver fibrosis; Diagnostic Test: Direct serum markers of liver fibrosis; Diagnostic Test: LiverTRAIL; Diagnostic Test: Cytokeratin 18; Diagnostic Test: Omics markers Sponsors: Maja Thiele; European Commission, H2020; Novo Nordisk A/S; University of Southern Denmark; Esbjerg University Hospital of South-West Jutland; Odense Municipality Alcohol Rehabilitation Unit; Svendborg Municipality Alcohol Rehabilitation Unit; University of Copenhagen; University of Oslo; Nordic Bioscience A/S; VLV Bio, Peviva AB; Manatee APS; Siemens Healthcare A/S; Steno Diabetes Center; Biomedical Research Foundation, Academy of Athens; European Molecular Biology Laboratory, EMBL, University of Heidelberg Recruiting
Fri, 13 Oct 2017 12:00:00 EDT
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Fri, 13 Oct 2017 16:14:00 -0400 California dietary supplement maker, Custompax prohibited from manufacturing A California dietary supplement manufacturer recently was ordered by a federal court to stop selling its products until the company comes into compliance with the U.S. Food and Drug Administration’s dietary supplement manufacturing regulations and other requirements listed in a consent decree.
Fri, 13 Oct 2017 08:31:00 -0400 FDA clears first 7T magnetic resonance imaging device Today, the U.S. Food and Drug Administration cleared the first seven tesla (7T) magnetic resonance imaging (MRI) device, more than doubling the static magnetic field strength available for use in the United States. The Magentom Terra is the first 7T MRI system cleared for clinical use in the United States.
Wed, 11 Oct 2017 11:52:00 -0400 FDA approves implantable device to treat moderate to severe central sleep apnea The U.S. Food and Drug Administration today approved a new treatment option for patients who have been diagnosed with moderate to severe central sleep apnea. The Remedē System is an implantable device that stimulates a nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing.
Fri, 06 Oct 2017 15:23:00 -0400 FDA awards 15 grants for clinical trials to stimulate product development for rare diseases The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country.
Fri, 06 Oct 2017 10:33:00 -0400 FDA awards six grants for natural history studies in rare diseases The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to inform medical product development by better understanding how specific rare diseases progress over time. One potential application of these studies is the opportunity to eventually use natural history models to augment the need for placebo arms in studies of drugs that target very rare disease, where trial recruitment can be challenging.
Fri, 06 Oct 2017 10:32:00 -0400 FDA approves first test for screening Zika virus in blood donations The U.S. Food and Drug Administration today approved the cobas Zika test, a qualitative nucleic acid test for the detection of Zika virus RNA in individual plasma specimens obtained from volunteer donors of whole blood and blood components, and from living organ donors.
Thu, 05 Oct 2017 17:04:00 -0400
Diabetes news from the American Diabetes Association
